Biodesix, Inc. (NASDAQ:BDSX) Short Interest Down 48.4% in January

Biodesix, Inc. (NASDAQ:BDSX) was the target of a significant decrease in short interest during the month of January. As of January 30th, there was short interest totaling 249,443 shares, a decrease of 48.4% from the January 15th total of 483,591 shares. Currently, 4.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 419,332 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 419,332 shares, the short-interest ratio is presently 0.6 days. Currently, 4.5% of the shares of the stock are short sold.

Analyst Ratings Changes

Several research firms recently commented on BDSX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Wall Street Zen raised Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $32.50.

Biodesix Trading Down 0.5%

Shares of Biodesix stock opened at $10.35 on Thursday. The firm has a market capitalization of $82.34 million, a price-to-earnings ratio of -1.86 and a beta of 0.67. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $20.40. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The stock has a 50 day moving average of $8.34 and a 200 day moving average of $7.96.

Key Headlines Impacting Biodesix

Here are the key news stories impacting Biodesix this week:

• Positive Sentiment: Significant month‑end short interest drop (Jan. 30) — short interest fell about 48% to ~249k shares (~4.5% of float), reducing immediate short‑selling pressure and days‑to‑cover; this is supportive if the trend holds.
• Positive Sentiment: Some institutional buying reported in recent quarters (e.g., Aberdeen added shares in Q4), indicating selective investor interest from funds alongside other portfolio moves.
• Neutral Sentiment: Scheduled earnings and investor call are a near‑term catalyst — Biodesix will report Q4 and full‑year 2025 results after the close on Feb. 26 and host a 4:30 PM ET webcast; the event could swing the stock depending on results and guidance. Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
• Neutral Sentiment: Recent short‑interest prints for Feb. 10–11 show “0 shares” (likely a reporting/data anomaly). Treat those entries cautiously until exchanges/data vendors correct them; they create short‑term ambiguity in the market picture.
• Negative Sentiment: CEO Scott Hutton sold 3,559 shares (~$10.08 avg), reducing his stake ~7.3% — multiple executive sales can be a negative sentiment signal for investors. Insider Selling: Biodesix CEO Sells 3,559 Shares
• Negative Sentiment: CFO Robin Harper Cowie sold 941 shares at ~$10.08 (SEC filing). Executive selling by multiple officers (CFO, CAO, CCO, CDO) on the same date amplifies negative market perception. CFO Form 4
• Negative Sentiment: Other insiders sold on Feb. 10: Gary Pestano (540 sh), Kieran O’Kane (584 sh), Chris Vazquez (101 sh) — the cluster of small/medium insider sales likely contributes to intraday weakness. (See SEC filings for details.) Insider Sales SEC Filings

Insider Transactions at Biodesix

In other Biodesix news, Director Jack W. Schuler purchased 20,000 shares of the firm’s stock in a transaction dated Monday, January 26th. The shares were purchased at an average cost of $11.80 per share, with a total value of $236,000.00. Following the completion of the purchase, the director owned 1,563,210 shares in the company, valued at approximately $18,445,878. This represents a 1.30% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Scott Hutton sold 3,559 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total transaction of $35,874.72. Following the transaction, the chief executive officer owned 45,413 shares in the company, valued at $457,763.04. The trade was a 7.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 7,672 shares valued at $73,576. 30.10% of the stock is owned by corporate insiders.

Institutional Trading of Biodesix

Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC acquired a new position in Biodesix in the third quarter valued at about $113,000. Oracle Investment Management Inc. purchased a new stake in shares of Biodesix in the 3rd quarter valued at approximately $113,000. Geode Capital Management LLC raised its stake in shares of Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after acquiring an additional 2,235 shares during the period. Monashee Investment Management LLC lifted its holdings in shares of Biodesix by 12.3% in the 4th quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock worth $764,000 after acquiring an additional 12,348 shares during the last quarter. Finally, XTX Topco Ltd boosted its position in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares during the period. 20.96% of the stock is currently owned by hedge funds and other institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.